Celiac disease testing is most reliable before a person starts a gluten-free diet. Celiac blood tests look for immune antibodies produced in response to gluten, and an intestinal biopsy looks for gluten-related injury. When gluten is removed, antibody levels may fall and the intestinal lining may begin to heal. The result can be a falsely reassuring blood test, a less conclusive biopsy, and months of avoidable diagnostic uncertainty.
Direct answer: If celiac disease is possible, complete celiac serology - and usually any planned small-intestinal biopsy - while you are still eating gluten. The usual first-line blood-test combination is tissue transglutaminase IgA (tTG-IgA) plus total IgA. Do not start or restart a gluten challenge on your own if prior reactions were severe; discuss it with a qualified healthcare professional.
Ulta Lab Tests provides direct online access to relevant testing where available, including a reflex-based Celiac Disease Comprehensive Panel. Laboratory testing supplies objective information, but it does not replace a medical history, examination, gastroenterology evaluation, or professional interpretation.
Celiac disease is a chronic immune-mediated condition in which gluten from wheat, barley, and rye triggers inflammation and injury in the small intestine in genetically susceptible people. The finger-like villi that help absorb nutrients may become shortened or flattened, reducing absorption of iron, folate, vitamin B12, calcium, vitamin D, and other nutrients.
Celiac disease is not simply a food intolerance. It is an autoimmune disorder that can affect the digestive tract, blood, bones, liver, nervous system, skin, and reproductive health. Some people have diarrhea, abdominal pain, or bloating. Others first come to medical attention because of iron-deficiency anemia, fatigue, low bone density, elevated liver enzymes, neuropathy, mouth ulcers, infertility, or another autoimmune condition. Some have few obvious symptoms.
Symptoms alone cannot distinguish celiac disease from irritable bowel syndrome, lactose intolerance, inflammatory bowel disease, infection, medication effects, wheat allergy, or non-celiac gluten sensitivity. Objective testing helps organize the differential diagnosis, but the final clinical interpretation may require serology, biopsy, dietary history, and specialist review.
Short answer: Celiac serology and duodenal biopsy detect the body's response to gluten. Removing the trigger can lower antibody concentrations and begin repairing the tissue changes the tests are designed to find.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) advises against starting a gluten-free diet before diagnostic testing because the diet can affect results. The 2026 British Society of Gastroenterology guideline makes the same point as a strong recommendation supported by high-certainty evidence.
Testing after gluten restriction can create several problems:
The practical sequence is simple: test first, confirm the diagnosis, then change the diet with appropriate clinical guidance.
Do not assume a negative antibody result rules celiac disease out, and do not independently restart a large amount of gluten. A clinician may review how long gluten has been restricted, how much was previously eaten, the severity of prior reactions, pregnancy status, anemia, weight loss, neurologic symptoms, and other risks.
Selected patients may begin with HLA typing for celiac disease. Absence of both HLA-DQ2 and HLA-DQ8 makes celiac disease highly unlikely and may avoid an unnecessary challenge. A positive HLA result only shows susceptibility. When a challenge is still needed, the 2026 British guideline uses 3 to 6 grams of gluten daily for at least six weeks as an adult reference protocol, but the amount, duration, and safety plan should be individualized and supervised.
Ongoing small-intestinal injury can impair nutrient absorption and contribute to anemia, low vitamin or mineral levels, reduced bone density, fatigue, weakness, neurologic symptoms, and abnormal liver enzymes. Celiac disease also clusters with type 1 diabetes and autoimmune thyroid disease. In children, untreated disease may affect growth and puberty; in adults, it may present through bone, blood, reproductive, skin, or neurologic findings rather than classic diarrhea.
Early awareness matters because the diagnosis carries a specific treatment and follow-up pathway. It also helps relatives and clinicians make informed decisions about testing. However, population-wide screening is not routinely recommended in current U.S. guidance; case finding focuses on symptoms, laboratory abnormalities, associated conditions, and higher-risk family history.
Testing may be reasonable when symptoms, laboratory findings, autoimmune history, or family history raise concern. The table below connects common clues with medically appropriate tests; it is not a recommendation that every reader order every test.
| Symptom or risk factor | What it may suggest | Related lab tests that may provide more information |
|---|---|---|
| Chronic diarrhea, constipation, bloating, gas, abdominal pain, or unexplained weight loss | Possible malabsorption or another digestive disorder | Celiac Disease Comprehensive Panel, tTG-IgA, and total IgA |
| Unexplained anemia, low ferritin, fatigue, weakness, or shortness of breath | Iron deficiency or another anemia pattern; celiac disease may be one cause | CBC with Differential and Platelets and Ferritin, Iron and TIBC Panel, together with celiac serology |
| Low vitamin B12 or folate, mouth ulcers, tingling, or neuropathy | Nutrient deficiency, malabsorption, or another neurologic/hematologic cause | Vitamin B12 and Folate Panel, CBC, and celiac serology |
| Low vitamin D, low bone density, fracture, bone pain, or muscle weakness | Impaired vitamin D/calcium status or another bone-health problem | Vitamin D 25-Hydroxy Test, Calcium Test, and selected PTH Intact Test, plus celiac serology |
| Unexplained elevated ALT or AST, low albumin, or other liver-related abnormalities | Celiac-associated liver abnormalities or another liver/metabolic condition | Comprehensive Metabolic Panel and celiac serology |
| Autoimmune thyroid disease, type 1 diabetes, selective IgA deficiency, or another associated condition | Higher clinical suspicion for celiac disease | Celiac serology; TSH with Reflex to Free T4 when thyroid status needs evaluation |
| First-degree relative with confirmed celiac disease | Increased inherited susceptibility | Celiac serology while eating gluten; HLA-DQ2/DQ8 in selected uncertain cases |
| Itchy blistering rash suggestive of dermatitis herpetiformis | A skin manifestation that can be associated with celiac disease | Celiac serology and prompt dermatology/gastroenterology evaluation; skin biopsy may be needed |
Safety note: Seek urgent medical care for black or bloody stools, severe or worsening abdominal pain, persistent vomiting or dehydration, marked shortness of breath, confusion, progressive weakness or neurologic change, or rapid unintentional weight loss. Direct-access retesting is not a substitute for urgent evaluation.
Blood tests can identify celiac-associated antibodies, detect total IgA deficiency that could invalidate an IgA-based result, and show connected anemia, iron depletion, nutrient abnormalities, liver-marker changes, or thyroid dysfunction. Repeating the antibody that was initially abnormal can also contribute to follow-up after a confirmed diagnosis.
Blood tests cannot show the exact degree of intestinal injury, prove that gluten caused every symptom, distinguish every gluten-related disorder, or guarantee that the intestine has healed. A normal result obtained after gluten restriction may be misleading. Even after treatment, normalized antibodies do not always equal mucosal healing; current guidance recognizes duodenal histology as the direct assessment of persistent intestinal inflammation.
No single result should be interpreted in isolation. Diet, total IgA status, age, symptoms, medications, pretest probability, assay method, and the result's relationship to the laboratory's upper limit of normal all matter.
| Lab test or panel | What it measures | Why it may be relevant | What results may generally suggest | Important limitations |
|---|---|---|---|---|
| Celiac Disease Comprehensive Panel | tTG-IgA and total IgA, with result-dependent reflex testing described on the product page | A focused first-line option that pairs the preferred IgA antibody with an IgA-deficiency check | Elevated tTG-IgA with adequate total IgA increases suspicion; low IgA changes the appropriate antibody pathway | Must be performed while eating gluten; reflex components and charges can depend on results; positive serology usually needs clinical confirmation |
| Tissue Transglutaminase IgA Antibody | IgA antibodies directed against tissue transglutaminase | Preferred first-line celiac antibody for most patients | A higher result, especially far above the assay upper limit, raises the probability of celiac disease | Can be falsely negative with low gluten exposure, mild disease, IgA deficiency, or immunosuppression; assay ranges vary |
| Total IgA | Overall immunoglobulin A concentration | Shows whether an IgA-based celiac result can be trusted | Low or absent IgA may indicate selective IgA deficiency and the need for IgG-based testing; high IgA is nonspecific | Does not test for celiac antibodies or active intestinal injury |
| Endomysial IgA Antibody Screen with Reflex to Titer | IgA antibodies against endomysial targets | A highly specific confirmatory antibody in selected pathways or reflex panels | A positive result supports a celiac pattern, particularly when tTG-IgA is strongly elevated | Qualitative and operator-dependent; less useful with IgA deficiency or after gluten restriction; not a stand-alone diagnosis |
| tTG-IgG and DGP IgG/IgA Antibodies | IgG antibodies to tissue transglutaminase or deamidated gliadin peptide, with DGP product also measuring IgA | Most useful when confirmed IgA deficiency makes tTG-IgA unreliable; DGP may have selected pediatric or specialist uses | A positive IgG result in an IgA-deficient patient may support further evaluation | Isolated tTG-IgG in a person with normal IgA has poor accuracy; broad antibody panels can create confusing false-positive patterns |
| HLA Typing for Celiac Disease | Genetic susceptibility markers HLA-DQ2 and HLA-DQ8 | Helpful when gluten was removed before testing, serology and biopsy conflict, or the original diagnosis is uncertain | Absence of both markers makes celiac disease highly unlikely; presence shows susceptibility only | Many healthy people carry these markers; a positive result does not show active disease or intestinal damage |
| CBC with Differential and Platelets | Hemoglobin, hematocrit, red-cell indices, white cells, and platelets | Looks for anemia and other blood-count abnormalities that may accompany malabsorption | Low hemoglobin and altered red-cell indices may suggest iron, folate, or B12 deficiency, depending on the pattern | Anemia has many causes; a normal CBC does not rule out celiac disease or early nutrient depletion |
| Ferritin, Iron and TIBC Panel | Iron stores, circulating iron, binding capacity, and calculated saturation | Iron deficiency can be the first or only recognized celiac manifestation | Low ferritin usually supports depleted iron stores; low saturation can support iron-restricted erythropoiesis | Ferritin can rise with inflammation, liver disease, or iron overload; iron results require context and do not identify the cause |
| Vitamin B12 and Folate Panel | Serum vitamin B12 and folate | Evaluates nutrients involved in blood-cell production and neurologic function | Low results may reflect reduced intake, malabsorption, medication effects, or another condition | Serum values have limitations; borderline B12 may need additional evaluation; normal values do not test for intestinal injury |
| Vitamin D 25-Hydroxy, Calcium, and selected PTH Intact | Vitamin D status, circulating calcium, and parathyroid response | Helps assess bone-related consequences of malabsorption | Low vitamin D or calcium with elevated PTH may suggest a compensatory response, but patterns vary | Serum calcium can remain normal despite poor bone mineralization; DXA imaging, history, kidney function, and other factors may be needed |
| Comprehensive Metabolic Panel | Liver enzymes, albumin, total protein, calcium, electrolytes, glucose, and kidney markers | Screens for liver-related abnormalities, low protein, electrolyte changes, and overall metabolic context | Elevated aminotransferases or low albumin may warrant evaluation; patterns are not specific to celiac disease | Does not measure celiac antibodies and cannot determine the cause of an abnormal liver or protein result |
| TSH with Reflex to Free T4 | TSH, with Free T4 added when the reflex rule is met | Autoimmune thyroid disease can coexist with celiac disease and mimic fatigue, weight, or bowel symptoms | High or low TSH may indicate thyroid dysfunction requiring interpretation with Free T4 and clinical context | Does not test for celiac disease; illness, pregnancy, medications, supplements, and pituitary factors may affect results |
| Selected Magnesium, Zinc, and Copper tests | Circulating mineral concentrations | May be considered with severe, prolonged, or documented malabsorption | Low results may support deficiency, while high results can reflect supplementation or other disorders | Not routine for every patient; serum concentrations may not perfectly represent tissue stores and should not be ordered indiscriminately |
For most adults with a compatible symptom or risk pattern, begin with tTG-IgA plus total IgA. The Celiac Disease Comprehensive Panel combines this core pair and uses result-dependent reflex testing. Ordering both the panel and the same individual components may duplicate testing.
When celiac serology is positive or suspicion is substantial, a clinician may select a CBC, iron panel, B12 and folate panel, 25-hydroxy vitamin D, calcium, CMP, and thyroid testing. Magnesium, zinc, copper, PTH, or other tests should follow a specific clinical reason rather than a broad everyone-needs-everything approach.
The 2023 American College of Gastroenterology guideline recommends upper endoscopy with multiple duodenal biopsies for confirmation in adults and children with suspected celiac disease. The patient should generally remain on a gluten-containing diet until the diagnostic process is complete.
2026 adult guideline update: The British Society of Gastroenterology now conditionally allows an optional no-biopsy diagnosis for symptomatic adults evaluated in secondary care when IgA-tTG is at least 10 times the assay's upper limit of normal, after shared decision-making. This is a specialist pathway, not a self-diagnosis rule. U.S. guidance still generally favors biopsy confirmation for adults; highly elevated results should prompt gastroenterology review.
Follow-up may include symptoms, weight, dietary review, the celiac antibody that was initially abnormal, CBC, iron markers, folate, B12, vitamin D, calcium, and liver tests. The 2026 British guideline describes reviews around 3 to 6 months and 12 to 24 months, but timing should be individualized. Falling antibodies support reduced exposure; they do not guarantee mucosal healing.
This pattern raises suspicion for celiac disease. Probability generally increases as the result rises relative to the assay's upper limit of normal. The result should be paired with symptoms, risk, and gastroenterology guidance; most U.S. adults still undergo biopsy confirmation.
The IgA-based result may be unreliable because the person may not produce enough IgA. IgG-based serology and gastroenterology evaluation are more appropriate than treating the negative tTG-IgA as an exclusion.
Celiac disease becomes less likely when gluten exposure has been adequate and pretest probability is low or moderate. It is not impossible. Limited gluten intake, mild disease, laboratory variability, immunosuppressive treatment, or seronegative celiac disease can produce a negative result. Persistent iron deficiency, weight loss, severe diarrhea, malabsorption, or other high-suspicion findings warrant clinical follow-up.
A positive result means genetic susceptibility, not active celiac disease. A negative result for both DQ2 and DQ8 makes celiac disease highly unlikely and is the more useful outcome diagnostically.
Use the range printed on the laboratory report. Celiac assays are not interchangeable, so the absolute number and its ratio to the upper limit of normal matter. Results can also be influenced by gluten intake, age, medications, immune status, pregnancy, recent illness, supplements, and laboratory method. Companion CBC, iron, CMP, and nutrient results may also vary with age, sex, fasting status, hydration, pregnancy, medications, supplements, recent illness, and methodology. An abnormal result is not automatically a diagnosis, and a normal result does not always rule out disease. Repeat testing should answer a defined clinical question.
Ulta Lab Tests allows patients to order many laboratory tests directly online where available, view transparent pricing before ordering, and complete collection through established laboratory networks such as Quest Diagnostics where applicable. No insurance is required, eligible HSA/FSA payment may be available where accepted, and results are delivered through a secure online account.
The celiac disease testing category brings together focused celiac antibodies, reflex panels, and selected genetic testing. Direct access can make it easier to obtain objective information, but it should be used to support - not replace - a qualified healthcare professional's evaluation. Availability, collection requirements, and reflex charges can vary by test and location; review the product page before ordering.
No. Celiac antibodies are produced in response to gluten exposure, so reducing or removing gluten can lower the signal the test is meant to detect. Continue your usual gluten-containing diet until testing and any planned biopsy are complete, unless a qualified clinician advises otherwise. If you already stopped gluten, ask about the safest diagnostic strategy before changing your diet again.
For most people, current guidance starts with tTG-IgA and total IgA. tTG-IgA is the preferred first-line antibody, while total IgA identifies IgA deficiency that could make the antibody result falsely negative. A reflex-based celiac panel can combine these steps. The appropriate pathway may differ for young children, people with IgA deficiency, or those already eating gluten-free.
If you have not restricted gluten and normally eat it in at least one meal daily, current adult guidance supports continuing that usual diet. If gluten has already been removed, do not improvise a challenge. One 2026 adult guideline uses 3 to 6 grams daily for at least six weeks, but symptom severity, pregnancy, anemia, neurologic concerns, and other factors may require a different supervised plan.
Usually not for a U.S. adult. Positive serology identifies a pattern that warrants clinical review, and current American College of Gastroenterology guidance generally recommends upper endoscopy with multiple duodenal biopsies for confirmation. A newer British guideline permits a specialist-led no-biopsy pathway for selected symptomatic adults with tTG-IgA at least 10 times the upper limit of normal, but this is not a direct-access self-diagnosis rule.
Yes. tTG, EMA, and DGP antibodies may fall after gluten is removed, and the small intestine may begin to heal. A negative result obtained after restriction therefore may not reflect the person's untreated state. Interpretation depends on prior gluten exposure, total IgA, symptoms, medications, and clinical risk. HLA testing or a medically supervised gluten challenge may be considered in selected cases.
First confirm that total IgA is adequate and that gluten exposure was sufficient. A negative tTG-IgA makes celiac disease less likely, but high-suspicion features such as persistent iron deficiency, weight loss, malabsorption, severe diarrhea, or a strong family history may justify gastroenterology review and possibly biopsy. Other digestive, endocrine, medication-related, or nutritional causes should also be evaluated.
No. These genetic variants are common, and many carriers never develop celiac disease. HLA testing is more powerful when it is negative: absence of both DQ2 and DQ8 makes celiac disease highly unlikely. A positive result only indicates susceptibility and must be interpreted with gluten exposure, antibody testing, symptoms, and, when appropriate, biopsy findings.
No. Symptoms may improve because wheat contains fermentable carbohydrates, because another food changed at the same time, or because of non-celiac gluten sensitivity, wheat allergy, irritable bowel syndrome, or another mechanism. Improvement is meaningful to discuss with a clinician, but it is not specific enough to establish celiac disease. Complete validated testing before restriction whenever medically safe.
Ulta Lab Tests offers direct online access to many celiac blood tests where available, including tTG-IgA, total IgA, reflex panels, and HLA typing. Direct access can help you obtain objective information and transparent pricing, but a positive, negative, or discordant result should be reviewed with a qualified healthcare professional. Endoscopy, biopsy, gluten-challenge decisions, and a lifelong diagnosis require clinical care.
Timing depends on age, initial antibody level, symptoms, deficiencies, and the care plan. The 2026 British adult guideline describes follow-up around 3 to 6 months and again at 12 to 24 months. Clinicians may repeat the antibody that was initially abnormal along with CBC, iron, vitamins, or liver markers that need follow-up. Normalized antibodies do not prove complete intestinal healing.
No. Celiac disease is an immune-mediated intestinal disorder associated with specific antibodies, genes, and tissue injury. Wheat allergy is an allergic reaction evaluated through a different history and testing pathway. Non-celiac gluten sensitivity is considered after celiac disease and wheat allergy are excluded. A generic food-sensitivity panel should not replace validated celiac serology.
First-degree relatives of a person with confirmed celiac disease have higher risk than the general population. Testing decisions depend on symptoms, age, autoimmune history, and prior results. Serology must be performed while the relative is eating gluten. HLA testing can sometimes clarify long-term susceptibility, but a positive gene result does not diagnose active disease.
Celiac disease testing works best when it captures the immune and intestinal response before gluten is removed. For most people, the focused starting point is tTG-IgA plus total IgA while eating a gluten-containing diet, followed by the appropriate clinical confirmation. IgG-based antibodies, EMA, HLA typing, and broader nutrient or organ testing each have specific roles; none should become an indiscriminate substitute for a clear diagnostic pathway.
Explore celiac disease blood tests and panels through Ulta Lab Tests, review each product's preparation and reflex details, and discuss results with a qualified healthcare professional before committing to a lifelong gluten-free diet.
Celiac disease is a chronic immune-mediated disorder in which gluten triggers small-intestinal injury in genetically susceptible people. Celiac disease testing should occur while gluten is still being eaten because gluten restriction can lower antibodies and heal intestinal tissue, creating falsely reassuring results.
Related lab tests: Celiac Disease Comprehensive Panel; tTG-IgA; total IgA; EMA-IgA; tTG-IgG; DGP-IgG/IgA antibodies; HLA-DQ2/DQ8; CBC; ferritin, iron and TIBC; vitamin B12 and folate; 25-hydroxy vitamin D; calcium; CMP; and TSH with reflex to Free T4.
Ulta Lab Tests provides direct online access to many relevant celiac disease tests and panels where available.
Disclaimer: Lab testing is informational and should be interpreted with a qualified healthcare provider; it does not replace professional diagnosis, biopsy decisions, treatment, or individualized medical advice.
These are the core tests. Testing should generally occur while the patient is still consuming gluten.
IgG-based testing is most relevant when total IgA confirms IgA deficiency or another defined clinical reason exists.
A negative result for the relevant HLA variants can make celiac disease very unlikely. A positive result indicates susceptibility but does not diagnose active celiac disease.
These mineral tests are risk-based.
The companion tests assess possible anemia, malabsorption, nutritional deficiencies, bone effects, liver abnormalities, or associated thyroid disease. They do not directly diagnose or exclude celiac disease.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
